News
Hosted on MSN20d
AXSM Stock Down Despite ADHD Study Meeting Primary EndpointImage Source: Zacks Investment Research The double-blind, placebo-controlled phase III FOCUS study evaluated solriamfetol versus placebo in adults with ADHD ... The stock price decline could ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback